May 9, 2023 -- Adaptive Biotechnologies on Tuesday announced that the U.S. Food and Drug Administration (FDA) has accepted an investigational new drug (IND) application submitted by its collaborator, Genentech, for a neoantigen-directed T-cell receptor (TCR)-based T-cell therapy.
This IND is the first TCR-based therapy drug candidate to advance to clinical development from Adaptive Biotechnologies' oncology collaboration with Genentech, a member of the Roche Group.
Under the terms of the collaboration agreement signed in 2019, Genentech has responsibility for clinical, regulatory, and commercialization efforts for any T-cell therapy product candidate.
The collaboration utilizes Genentech's cancer immunotherapy research and development expertise and Adaptive's proprietary T-cell receptor (TCR) discovery platform, with the aim of developing tailored cellular therapy for each patient's individual cancer, the firms said.
Already have an account? Sign in Here
To access all ScienceBoard content create a free account now: